A global pharmaceutical company focused on developing medicines to treat substance use disorders (SUD) and serious mental illnesses, Indivior (NASDAQ:INDV) reported its financial results Thursday for the first quarter of the year. For the three months ended March 31st, the Richmond, Virginia-headquartered company disclosed net revenue of $284 million, up by 12% from $253 million in the same period of 2023. "Our first quarter results reflect continued double-digit top-line momentum led by SUBLOCADE (buprenorphine extended-release)," stated Indivior CEO Mark Crossley. “The underlying demand for this transformative treatment for moderate-to-severe opioid use disorder (OUD) remains strong and our strategy to expand prescribing in the justice system is delivering excellent results. SUBLOCADE's reported growth was, ...